Evidence map›Paper›PMID 39110739›Full record

ArticlePloS one2024

Risk factors of bloodstream infection after allogeneic hematopoietic cell transplantation in children/adolescent and young adults.

Daichi Sajiki, Hideki Muramatsu, Manabu Wakamatsu, Daiki Yamashita, Ryo Maemura, Yusuke Tsumura, Masayuki Imaya, Ayako Yamamori, Kotaro Narita, Shinsuke Kataoka and 4 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daichi SajikiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0003-4262-683X
Hideki MuramatsuDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0002-8801-0021
Manabu WakamatsuDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Daiki YamashitaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Ryo MaemuraDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yusuke TsumuraDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Masayuki ImayaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Ayako YamamoriDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0003-4002-2370
Kotaro NaritaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Shinsuke KataokaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Rieko TaniguchiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Atsushi NaritaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Nobuhiro NishioDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yoshiyuki TakahashiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is a crucial treatment for various diseases, including hematological malignancies, solid tumors, and genetic disorders. Despite its curative potential, HCT is associated with severe complications, notably infections, graft-versus-host disease, and organ damage. Infections, particularly bloodstream infections (BSIs), pose a significant threat in the initial weeks post-HCT, necessitating effective management strategies. This retrospective study aimed to clarify the incidence, pathogens, and risk factors associated with BSI within the first 30 days after allogeneic HCT in children/adolescents and young adults (AYAs). The study included 115 patients aged <31 years who underwent 121 allogeneic HCTs at the Department of Pediatrics, Nagoya University Hospital between January 1, 2018, and March 31, 2022. Data encompassed demographic characteristics, HCT details, and BSI information. Overall, 27 of 121 patients developed BSI with the cumulative incidence of 23.5% (95% confidence intervals [CI]: 17.0%-30.6%) at 30 days after HCT. The median onset time of BSI was 7 (range, 4-26 days) after HCT. Gram-positive bacteria accounted for 89% of pathogens isolated from blood cultures, with Streptococcus mitis/oralis being the most common. In multivariable analysis, tandem HCT (subdistribution hazard ratio [SHR]: 5.67, 95% CI: 2.74-11.7, p < 0.001) and peripherally inserted central catheters (SHR: 2.96, 95% CI: 1.34-6.55, p  =  0.007) were identified as independent risk factors for BSI. In patients receiving tandem HCT, the pathogens isolated from blood cultures were all gram-positive bacteria, with Streptococcus mitis/oralis accounting for up to 67% of the isolated pathogens. Tandem HCT and PICCs were identified as independent risk factors for BSI after allogeneic HCT in children/AYAs. The pathogens were commonly gram-positive, and Streptococcus mitis/oralis is important in patients who received tandem HCT. These data can provide valuable information for future studies to consider effective interventions to reduce the risk of BSI in high-risk patients.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultBacteremiaChildChild, PreschoolFemaleHumansIncidenceInfantMaleRetrospective StudiesRisk FactorsTransplantation, HomologousYoung Adult

Identifiers

PMID39110739
PMCPMC11305574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.